Protocol Ledger

NCT04762069 · Phase II · ACTIVE NOT RECRUITING

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Interventional Phase II clinical trial protocol NCT04762069 sponsored by CNS Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-18 Enrollment: 252 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04762069
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)252 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04762069
Protocol FieldVerified Registry Value
NCT IdentifierNCT04762069
Consolidated Lead SponsorCNS Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment252 participants (ACTUAL)
Registered Start Date2021-05-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI